BiotechTube
Home/Pipeline/RP1208

RP1208

Not Specified

Not SpecifiedActive

Key Facts

Indication
Not Specified
Phase
Not Specified
Status
Active
Company
Reviva Pharmaceuticals

About Reviva Pharmaceuticals

Reviva Pharmaceuticals is a late-stage, publicly traded biotech company developing next-generation therapeutics for CNS and other disorders. Its lead asset, brilaroxazine, has completed a pivotal Phase 3 trial in schizophrenia but requires an additional Phase 3 study per FDA feedback before an NDA submission. The company faces significant financial and clinical development risks but holds a novel, patented compound with a broad potential label across several large-market psychiatric indications.

View full company profile

Therapeutic Areas

Central Nervous SystemCardiovascularMetabolicInflammatoryRespiratory

Other Not Specified Drugs

DrugCompanyPhase
Inflammation ProgramsArcus BiosciencesNot Specified
Bone Marrow Conditioning ProgramTelix PharmaceuticalsPipeline
AGMB-447Agomab TherapeuticsNot Disclosed
AGMB-101Agomab TherapeuticsNot Disclosed
TRIFERTY-ATM®Laboratorio Reig JofreApproved/Commercial
AGEN1571 (anti-ILT2)AgenusNot specified
AGEN1777AgenusNot specified
AGEN1721AgenusNot specified
INCAGN1876 (GITR Agonist)AgenusNot specified
INCAGN1949 (OX40 Agonist)AgenusNot specified
AGEN1327 (anti-TIGIT)AgenusNot specified
AGEN2373 (CD137 Agonist)AgenusNot specified